Genocea Biosciences, Inc. Stock price

Equities

GNCAQ

US3724274010

Biotechnology & Medical Research

Market Closed - OTC Markets 11:27:28 2024-03-19 am EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Genocea Biosciences, Inc. 0.00% 0.00%
Sales 2020 1.36M Sales 2021 1.64M Capitalization 66.64M
Net income 2020 -43M Net income 2021 -33M EV / Sales 2020 50.8 x
Net cash position 2020 55.9M Net cash position 2021 19.96M EV / Sales 2021 28.4 x
P/E ratio 2020
-2.18 x
P/E ratio 2021
-2.4 x
Employees 74
Yield 2020 *
-
Yield 2021
-
Free-Float 99.84%
More Fundamentals * Assessed data
Dynamic Chart
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
2.90
5 years
0.00
Extreme 0
11.28
10 years
0.00
Extreme 0
191.92
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer 52 07-02-28
Corporate Officer/Principal - 18-12-09
Members of the board TitleAgeSince
Chairman 73 14-09-10
More insiders
Date Price Change Volume
24-03-28 - -100.00% 25

Delayed Quote OTC Markets, March 19, 2024 at 11:27 am EDT

More quotes
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
More about the company
  1. Stock
  2. Equities
  3. Stock Genocea Biosciences, Inc. - OTC Markets